Related references
Note: Only part of the references are listed.Therapeutic Effectiveness of Screening for Multiple Endocrine Neoplasia Type 2A
Andreas Machens et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
RET Cys634Arg mutation confers a more aggressive multiple endocrine neoplasia type 2A phenotype than Cys634Tyr mutation
Nuria Valdes et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
RET revisited: expanding the oncogenic portfolio
Lois M. Mulligan
NATURE REVIEWS CANCER (2014)
Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium
Andreas Machens et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2013)
Peak Incidence of Pheochromocytoma and Primary Hyperparathyroidism in Multiple Endocrine Neoplasia 2: Need for Age-Adjusted Biochemical Screening
Andreas Machens et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Individualization of Lymph Node Dissection in RET (Rearranged During Transfection) Carriers at Risk for Medullary Thyroid Cancer Value of Pretheropeutic Calcitonin Levels
Andreas Machens et al.
ANNALS OF SURGERY (2009)
Early malignant progression of hereditary medullary thyroid cancer
A Machens et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
RET codon 634 mutations in multiple endocrine neoplasia type 2:: Variable clinical features and clinical outcome
MK Puñales et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Share Paper
